Daily Endocrinology Research Analysis
Three high-impact studies advance endocrinology this cycle: (1) a multi-ancestry, life-course polygenic score markedly improves early prediction of obesity; (2) mechanistic work identifies mitochondrial proteostasis via LONP1 as a key determinant of β-cell survival in type 2 diabetes; and (3) semaglutide reshapes metabolic, inflammatory, and fibrotic pathways in MASH, with a 72-protein signature validated across cohorts.
Summary
Three high-impact studies advance endocrinology this cycle: (1) a multi-ancestry, life-course polygenic score markedly improves early prediction of obesity; (2) mechanistic work identifies mitochondrial proteostasis via LONP1 as a key determinant of β-cell survival in type 2 diabetes; and (3) semaglutide reshapes metabolic, inflammatory, and fibrotic pathways in MASH, with a 72-protein signature validated across cohorts.
Research Themes
- Genetic risk prediction for obesity across ancestries and the life course
- Mitochondrial proteostasis in pancreatic β-cell failure in type 2 diabetes
- GLP-1 receptor agonist mechanisms and biomarkers in steatohepatitis
Selected Articles
1. LONP1 regulation of mitochondrial protein folding provides insight into beta cell failure in type 2 diabetes.
Using human islets and mechanistic models, the authors show mitochondrial protein misfolding accumulates in T2D and that reduced LONP1 drives β-cell apoptosis and hyperglycemia. Enhancing LONP1 protects β cells via a chaperone-dependent, protease-independent mechanism, positioning mitochondrial proteostasis as a therapeutic target.
Impact: This is the first comprehensive demonstration that mitochondrial, not ER, proteotoxicity underpins β-cell failure in human T2D, and that LONP1-HSP70 activity is protective. It reframes therapeutic strategies toward mitochondrial proteostasis.
Clinical Implications: Targets enhancing mitochondrial protein folding (e.g., augmenting LONP1–mtHSP70 axis) could preserve β-cell mass and function in T2D. It motivates biomarker development for mitochondrial proteotoxic stress in β cells.
Key Findings
- Human T2D islets accumulate misfolded mitochondrial proteins, distinct from ER stress signatures.
- LONP1 expression is reduced in β cells from donors with T2D; LONP1 loss triggers β-cell apoptosis and hyperglycemia.
- LONP1 gain-of-function rescues β-cell survival after glucolipotoxicity via a protease-independent, HSP70-dependent mechanism.
- Mitochondrial proteostasis emerges as a central determinant of β-cell viability in T2D.
Methodological Strengths
- Integrates human donor islet proteomics with functional loss/gain-of-function experiments.
- Mechanistic dissection of LONP1 with chaperone dependency (mtHSP70) establishes causality.
Limitations
- Predominantly preclinical/experimental evidence; therapeutic translatability requires clinical studies.
- Human islet donor heterogeneity and limited sample sizes may constrain generalizability.
Future Directions: Develop small-molecule or biologic modulators of the LONP1–mtHSP70 axis; validate β-cell mitochondrial proteotoxicity biomarkers in longitudinal T2D cohorts; test β-cell–protective strategies in early T2D trials.
Protein misfolding is a contributor to the development of type 2 diabetes (T2D), but the specific role of impaired proteostasis is unclear. Here we show a robust accumulation of misfolded proteins in the mitochondria of human pancreatic islets from patients with T2D and elucidate its impact on β cell viability through the mitochondrial matrix protease LONP1. Quantitative proteomics studies of protein aggregates reveal that islets from donors with T2D have a signature resembling mitochondrial rather than endoplasmic reticulum protein misfolding. Loss of LONP1, a vital component of the mitochondrial proteostatic machinery, with reduced expression in the β cells of donors with T2D, yields mitochondrial protein misfolding and reduced respiratory function, leading to β cell apoptosis and hyperglycaemia. LONP1 gain of function ameliorates mitochondrial protein misfolding and restores human β cell survival after glucolipotoxicity via a protease-independent effect requiring LONP1-mitochondrial HSP70 chaperone activity. Thus, LONP1 promotes β cell survival and prevents hyperglycaemia by facilitating mitochondrial protein folding. These observations provide insights into the nature of proteotoxicity that promotes β cell loss during the pathogenesis of T2D, which could be considered as future therapeutic targets.
2. Polygenic prediction of body mass index and obesity through the life course and across ancestries.
A multi-ancestry BMI polygenic score built from up to 5.1 million participants explained 17.6% of BMI variance in Europeans, with lower performance in some non-European populations. Early-life prediction improved substantially, and higher genetic risk was linked to greater adult weight gain and weight regain after lifestyle interventions.
Impact: Demonstrates clinically meaningful, early-life obesity risk prediction across ancestries at unprecedented scale, informing precision prevention while highlighting equity gaps.
Clinical Implications: PGS can augment pediatric risk stratification and timing/intensity of prevention, but implementation must address reduced performance in some ancestries and integrate environmental determinants.
Key Findings
- Multi-ancestry BMI PGS explained 17.6% of variance in European-ancestry UK Biobank participants.
- Performance varied by ancestry (e.g., ~16% in East Asian-Americans vs 2.2% in rural Ugandans).
- Adding PGS to birth predictors nearly doubled explained variance for childhood BMI (e.g., 11% to 21% at age 8).
- Higher PGS associated with greater adult weight gain and modestly higher initial weight loss but greater regain in intervention trials.
Methodological Strengths
- Extremely large, multi-ancestry dataset (up to 5.1 million) with external validation.
- Life-course analyses (ALSPAC) and trial re-analyses linking genetics to intervention responses.
Limitations
- Substantially reduced performance in certain ancestries highlights portability limitations.
- PGS reflects probabilistic risk; environmental and social determinants remain critical and may confound associations.
Future Directions: Improve cross-ancestry portability via diverse training sets and functional fine-mapping; integrate PGS with environmental and clinical factors in implementation studies; evaluate ethical, equity, and behavioral impacts.
Polygenic scores (PGSs) for body mass index (BMI) may guide early prevention and targeted treatment of obesity. Using genetic data from up to 5.1 million people (4.6% African ancestry, 14.4% American ancestry, 8.4% East Asian ancestry, 71.1% European ancestry and 1.5% South Asian ancestry) from the GIANT consortium and 23andMe, Inc., we developed ancestry-specific and multi-ancestry PGSs. The multi-ancestry score explained 17.6% of BMI variation among UK Biobank participants of European ancestry. For other populations, this ranged from 16% in East Asian-Americans to 2.2% in rural Ugandans. In the ALSPAC study, children with higher PGSs showed accelerated BMI gain from age 2.5 years to adolescence, with earlier adiposity rebound. Adding the PGS to predictors available at birth nearly doubled explained variance for BMI from age 5 onward (for example, from 11% to 21% at age 8). Up to age 5, adding the PGS to early-life BMI improved prediction of BMI at age 18 (for example, from 22% to 35% at age 5). Higher PGSs were associated with greater adult weight gain. In intensive lifestyle intervention trials, individuals with higher PGSs lost modestly more weight in the first year (0.55 kg per s.d.) but were more likely to regain it. Overall, these data show that PGSs have the potential to improve obesity prediction, particularly when implemented early in life.
3. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.
Semaglutide ameliorated fibrosis and inflammation in preclinical MASH models and downregulated related hepatic gene pathways. A 72-protein serum signature associated with MASH resolution under semaglutide was identified and externally validated, suggesting reversion of the circulating proteome toward healthy patterns.
Impact: Links a widely used GLP-1RA to multi-omic changes underlying MASH resolution and provides a reproducible proteomic biomarker panel to track response.
Clinical Implications: Supports semaglutide’s disease-modifying potential in MASH and suggests a 72-protein panel for pharmacodynamic monitoring and possibly patient stratification.
Key Findings
- In two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation.
- Hepatic expression of fibrosis- and inflammation-related gene pathways was reduced with semaglutide.
- Aptamer-based proteomics identified 72 serum proteins associated with MASH resolution under semaglutide.
- An independent real-world cohort reproduced the 72-protein signature differences between MASH and healthy individuals.
Methodological Strengths
- Convergent evidence from two animal models and human clinical samples.
- External validation of a proteomic signature in an independent real-world cohort.
Limitations
- Ancillary, mechanistic analysis rather than a randomized clinical outcome study; causality for each protein is not established.
- Aptamer-platform biases and lack of detailed dosing/duration data in abstract limit interpretability.
Future Directions: Prospectively validate the 72-protein panel as a treatment-response biomarker; test if proteomic shifts predict histologic endpoints; explore combinatorial therapies targeting identified pathways.
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. Here we show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation and reduced hepatic expression of fibrosis-related and inflammation-related gene pathways. Aptamer-based proteomic analyses of serum samples from patients with MASH in a clinical trial identified 72 proteins significantly associated with MASH resolution and semaglutide treatment, with most related to metabolism and several implicated in fibrosis and inflammation. An independent real-world cohort verified the pathophysiological relevance of this signature, showing that the same 72 proteins are differentially expressed in patients with MASH relative to healthy individuals. Taken together, these data suggest that semaglutide may revert the circulating proteome associated with MASH to the proteomic pattern observed in healthy individuals.